CLINICAL IMMUNOLOGY
Elevated expression of interleukin-21 and its correlation to T-cell subpopulation in patients with ulcerative colitis
Submission date: 2015-03-01
Final revision date: 2015-04-12
Acceptance date: 2015-04-24
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):331-336
KEYWORDS
ABSTRACT
Objective: To investigate the expression of interleukin-21 (IL-21) and its correlation to T-cell subpopulation including Th1, Tc1 and Th17 cells in Ulcerative colitis (UC).
Material and methods: We examined the expression of IL-21, IL-17 and IFN-γin UC patients and controls by enzyme-linked immunosorbent assay (ELISA) and flow cytometry.
Results: We found that IL-21 was expressed on CD3+CD8-T cells by flow cytometry. Plasma IL-21 level and the percentage of CD3+CD8-IL-21+ T cells were significantly elevated in UC patients compared to controls. The percentage of CD3+CD8-IL-17+ T (Th17), CD3+CD8-IFN-γ+ T (Th1) and CD3+CD8+IFN-γ+ T (Tc1) cells was also significantly increased in UC patients. Moreover, we found a significant positive correlation between CD3+CD8-IL-21+T cells and Th17 cells.
Conclusions: Elevated IL-21 and its positive correlation to Th17 cells may play a role in the pathogenesis of UC.
Material and methods: We examined the expression of IL-21, IL-17 and IFN-γin UC patients and controls by enzyme-linked immunosorbent assay (ELISA) and flow cytometry.
Results: We found that IL-21 was expressed on CD3+CD8-T cells by flow cytometry. Plasma IL-21 level and the percentage of CD3+CD8-IL-21+ T cells were significantly elevated in UC patients compared to controls. The percentage of CD3+CD8-IL-17+ T (Th17), CD3+CD8-IFN-γ+ T (Th1) and CD3+CD8+IFN-γ+ T (Tc1) cells was also significantly increased in UC patients. Moreover, we found a significant positive correlation between CD3+CD8-IL-21+T cells and Th17 cells.
Conclusions: Elevated IL-21 and its positive correlation to Th17 cells may play a role in the pathogenesis of UC.
REFERENCES (43)
1.
Ekbom A, Helmick C, Zack M, et al. (1990): Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233.
2.
Sartor RB (2006): Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407.
3.
Lo WC, Arsenescu RI, Friedman A (2013): Mathematical model of the roles of T cells in inflammatory bowel disease, Bull Math Biol 75: 1417-1433.
4.
Takahashi M, Nakamura K, Honda K, et al. (2006): An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci 51: 677-686.
5.
Kappeler A, Mueller C (2000): The role of activated cytotoxic T cells in inflammatory bowel disease. Histol Histopathol 15: 167-172.
6.
Sunagawa T, Yonamine Y, Kinjo F, et al. (2001): HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis. J Clin Immunol 21: 381-389.
7.
Sad S, Marcotte R, Mosmann TR (1995): Cytokine-induced differentiationof precursor mouse CD8 T cells into cytotoxic CD8 T cellssecreting Th1 or Th2 cytokines. Immunity 2: 271-279.
8.
Croft M, Carter L, Swain SL, et al. (1994): Generation ofpolarized antigen-specific CD8 effector populations: reciprocal actionof interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180: 1715-1728.
9.
Moss RB, Moll T, El-Kalay M, et al. (2004): Th1/Th2 cells in inflammatory disease states: therapeutic implications. Expert Opin Biol Ther 4: 1887-1896.
10.
Coffman RL (2006): Origins of the T(H)1-T(H)2 model: a personal perspective. Nat Immunol 7: 539-541.
11.
Stockinger B, Veldhoen M (2007): Differentiation and function of Th17 T cells. Curr Opin Immunol 19: 281-286.
12.
Toda A, Piccirillo CA (2006): Development and function of naturally occurring CD4+CD25+ regulatory T cells. J Leukoc Biol 80: 458-470.
13.
Monteleone G, Pallone F, MacDonald TT (2008): Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 29: 290-294.
14.
Ogawara H, Handa H, Morita K, et al. (2003): High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 71: 283-288.
15.
Panitsas FP, Theodoropoulou M, Kouraklis A, et al. (2004): Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103: 2645-2647.
16.
Wang T, Zhao H, Ren H, et al. (2005): Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura, Haematologica 90: 914-923.
17.
Liu B, Zhao H, Poon MC, et al. (2007): Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 78: 139-143.
18.
Mitoma H, Horiuchi T, Kimoto Y, et al. (2005): Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 16: 609-615.
19.
Andersson AK, Feldmann M, Brennan FM (2008): Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J Immunol 68: 103-111.
20.
Fantini MC, Monteleone G, MacDonald TT (2008): IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunol 1: 110-115.
22.
Okazaki K, Morita M, Nishimori I, et al. (1993): Major histocompatibility antigen-restricted cytotoxicity in inflammatory bowel disease. Gastroenterology 104: 384-391.
23.
Abraham C, Cho J (2009): Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 15: 1090-1100.
24.
Spolski R, Leonard WJ (2008): The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 20: 295-301.
25.
Leonard WJ, Spolski R (2005): Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5: 688-698.
26.
Habib T, Nelson A, Kaushansky K (2003): IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 112: 1033-1045.
27.
Korn T, Bettelli E, Gao W, et al. (2007): IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487.
28.
Fina D, Fantini MC, Pallone F, et al. (2007): Role of interleukin-21 in inflammation and allergy. Inflamm Allergy Drug Targets 6: 63-68.
29.
Strengell M, Sareneva T, Foster D, et al. (2002): IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 169: 3600-3605.
30.
Fina D, Caruso R, Pallone F, et al. (2007): Interleukin-21 (IL-21) controls inflammatory pathways in the gut. Endocr Metab Immune Disord Drug Targets 7: 288-291.
31.
Caruso R, Fina D, Peluso I, et al. (2007): A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132: 166-175.
32.
Distler JH, Jüngel A, Kowal-Bielecka O, et al. (2005): Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 52: 856-864.
33.
Inoue S, Matsumoto T, Iida M, et al. (1999): Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 94: 2441-2446.
34.
Yamamoto-Furusho JK, Miranda-Perez E, Fonseca-Camarillo G, et al. (2010): Interleukin 21 expression is increased in rectal biopsies from patients with ulcerative colitis. Inflamm Bowel Dis 16: 1090.
35.
Monteleone G, Monteleone I, Fina D, et al. (2005): Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology 128: 687-694.
36.
Sarra M, Monteleone I, Stolfi C, et al. (2010): Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 16: 1332-1339.
37.
Fujino S, Andoh A, Bamba S, et al. (2003): Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
38.
Raza A, Yousaf W, Giannella R, et al. (2012): Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol 8: 161-168.
39.
Niu Q, Cai B, Huang ZC, et al. (2012): Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 32: 2731-2736.
40.
Becher B, Segal BM (2011): T(H)17 cytokines in autoimmune neuroinflammation. Curr Opin Immunol 23: 707-712.
41.
Young DA, Hegen M, Ma HL, et al. (2007): Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56: 1152-1163.
42.
Zhou L, Ivanov II, Spolski R, et al. (2007): IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967-974.
43.
De Nitto D, Sarra M, Pallone F, et al. (2010): Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol 16: 3638-3641.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
